No business can be successful without a solid business plan. In fact, a business plan could be the thing that makes or breaks your entrepreneurial enterprise, especially if you haven’t started a ...

Robots may not be taking the place of researchers in lab coats running clinical trials anytime soon, but AI is playing an increasingly important role in drug discovery efforts. That’s the message ...

Rachel is a freelancer based in Echo Park, Los Angeles and has been writing and producing content for nearly two decades on subjects ranging from tech to fashion, health and lifestyle to entertainment ...

After the FDA's landmark approval of the opioid-free acute pain reliever Journavx in January, Vertex Pharmaceuticals has hit a snag on its path to expand the potential blockbuster’s reach into ...

Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We conducted a phase 1–2 study of zimislecel ...

Vertex Pharmaceuticals (NASDAQ:VRTX) is scheduled to announce its earnings on Monday, May 5, 2025. For event-driven traders, understanding historical stock performance around earnings releases can be ...

Over the past 15 years, Vertex Pharmaceuticals has grown from a $7.5 billion market cap to over $120 billion as it’s commercialized several products. CRISPR Therapeutics won its first regulatory ...

-- JOURNAVX is the first and only approved non-opioid oral pain signal inhibitor and the first new class of pain medicine approved in more than 20 years -- -- JOURNAVX is an effective and ...

The healthcare sector has struggled to deliver worthwhile returns for investors since 2021, weighed down by several headwinds. Rising interest rates, challenges in the U.S. healthcare system, and the ...

Meta CEO Mark Zuckerberg told Joe Rogan earlier this month that Meta is developing new AI that will be able to write “a lot of the code in our apps.” OpenAI, meanwhile, is reportedly working on AI ...